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The shift from a predominant synthesis of prototype Th1 cytokines to Th2 or Th0 type of cytokines by
antigen activated PBMC’s from HIV infected humans and SIV infected disease susceptible rhesus
macaques (RM) has been shown to be associated with disease progression. Paradoxically, antigen
activated PBMC’s from sooty mangabeys (SM), which are naturally infected with SIVand are disease
resistant despite highviral loads, maintaina predominant Th2 cytokine proﬁle. It has beenreasoned that
the resistance to perturbations of cytokine synthesis by slow and/or nonprogressor HIVinfected patients
and SIVinfected disease susceptible RM is secondary to inherited polymorphisms within the promoter
regions for cytokines. Similar promoter polymorphisms could also contribute to the cytokine proﬁle of
PBMC’s from SM. To address this issue promoter regions for the major Th1/Th2 cytokines from RM
and SM were cloned and sequenced. Sequence analysis of promoter fragments of IL-4, IL-10, IL-12
p40, IFN-gamma and TNF-alpha from the two monkey species showed varying degree of homology
ranging from high degree of homology detected for IFN-gamma promoter (.99%) to relatively high
degree of polymorphism detected for TNF-alpha promoter (94% homology). In addition, several
variable regions within the promoters of IL-12 p40, IL-10 and TNF-alpha in the two species contain
polymorphisms in sequences that constitute binding sites of known transcription factors (TF). Such
differences are likely to differentially bind TF and thus either qualitatively and/or quantitatively affect
the regulation of cytokine synthesis in these two species and potentially contribute to disease
progression and/or resistance.
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INTRODUCTION
Both CD4þand CD8þ T cells mediate their biological
effect upon recognition of their cognate peptide-MHC
ligands in part by the synthesis of a spectrum of cytokines.
The quality and quantity of immune response generated is
in part governed by the spectrum of these cytokines. It has
been previously reported that disease progression in HIV
infected humans leads to a “shift” in the cytokine
expression proﬁle from a Th1 to Th2 prototype
characterized by defective production of interferon
gamma (IFN-gamma), IL-2 and IL-12 with a concomitant
increase in production of IL-4, IL-5, IL-6, and IL-10
(Klein et al., 1997) while the maintenance of the Th1 type
cytokine secretion pattern was found characteristic of
slow disease progression in the long term nonprogressor
(LTNP) HIV infected humans (Clerici et al., 1996). Other
study has however shown that PBMC from HIV infected
patients show a decreased ability to produce both Th1
(IFN-gamma) and Th2 (IL-4) cytokines and that high
frequency of clones generated from these cells exhibited
a Th0 phenotype (producing both Th1 and Th2 type
cytokines) that enhanced HIV replication (Maggi et al.,
1994). Similarly in SIV disease susceptible nonhuman
primates—such as cynomolgous macaques—pathogenic
SIV infection induces predominantly Th2 prototype
cytokines (Benveniste et al., 1996a) and an increase in
Th1 prototype cytokine IFN-gamma levels was associated
with better control of SIV infection with attenuated, but
not fully pathogenic virus (Benveniste et al., 1996b).
In vaccination experiments induction of IFN-gamma
production has been shown to correlate with protection to
rechallenge with pathogenic virus (Ahmed et al., 2002).
Natural SIV infection of nonhuman primates has
become an important model and a useful tool for studies
of the pathogenesis of lentivirus induced disease. The fact
that naturally SIV infected species—such as sooty
mangabeys (Cercocebus atys) (Fultz et al., 1986)—do
not develop SIV induced disease despite viral loads and
virus replication levels comparable to those in SIV
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especially attractive for studies aimed at deﬁning the
immune response mechanisms important for the “contain-
ment” as compared with development of the disease.
Interestingly, during the studies of Th phenotype of
CD4þ T cells from sooty mangabeys (SM), it was
discovered that despite the lifelong lack of SIV disease
T cell clones derived from both the SIV seronegative
and seropositive animals continuously demonstrate
predominantly a Th2 (or Th0) phenotype (Ansari et al.,
1994). This predominantly Th2/Th0 response observed in
SM irregardless of SIV status therefore represents an
interesting phenomenon since it is associated with disease
resistance rather than with accelerated disease
progression.
It has been hypothesized that one of the mechanisms
underlying the potential resistance to the lentivirus
induced perturbations in the expression of cytokines
synthesized by T cells could be due to genetically
inherited polymorphisms within the promoter regions for
these cytokines. However, studies aimed at deﬁning
promoter sequences in HIV infected patients with diverse
clinical stages produced controversial results. While some
studies have failed to demonstrate a link between select
polymorphisms in cytokine promoters for TNF-alpha
(Brinkman et al., 1997; Knuchel et al., 1998) and IFN-
gamma (Bream et al., 2000) and disease progression in
HIV infected patients, others have shown an association of
the 2308A polymorphism in the TNF-alpha promoter
with AIDS dementia (Quasney et al., 2001) and 2589T
polymorphism in the IL-4 promoter with an accelerated
switch from a NSI to a SI phenotype of HIV-1 and
potentially faster disease progression (Nakayama et al.,
2000).
Our studies with the nonhuman primate model of AIDS
prompted us to identify potential polymorphisms in
cytokine promoter sequences that may play a role in the
lentivirus infection and disease. Herewe analyze promoter
sequences of the cytokines characteristic for Th1 and
Th2 prototype response from both SIV disease susceptible
(rhesus macaque) and SIV disease resistant (sooty
mangabey) nonhuman primate species with the aim
to identify those that may underlie the differences in both
Th phenotype and SIV disease susceptibility observed in
these two species.
MATERIALS AND METHODS
Cells
The peripheral blood samples were obtained from normal
healthy adult rhesus macaques (Macaca mulatta) and adult
healthy SIV seronegative and seropositive sooty manga-
beys (Cercocebus atys) housed at the Yerkes Regional
Primate Research Center of EmoryUniversity. All animals
were maintained according to the guidelines of the
Committee on the Care and Use of Laboratory Animals of
the Institute of Laboratory Animal Resources, National
Research Council and the Health and Human Services
guidelines “Guide for the Care and Use of Laboratory
Animals.” Peripheral blood mononuclear cells (PBMC)
were isolated using Lymphocyte Separation Medium
(Cellgro, Herndon, VA).
Cloning of Promoter Sequences
DNAwas isolated from PBMC samples using the Wizard
Genomic DNA puriﬁcation kit (Promega, Madison, WI).
Promoter sequences were ampliﬁed utilizing primer
p a i r sa sf o l l o w s :5 0-GTGGCTCACACCTGTAATC-30
and 50-AGTTTATCAGGAGAAGCTAACGAT-30 for
IL-4 promoter; 50-TTTGGGAAGGGGAAGTAGGG-
ATAG-30 and 50-GGAGGACCAGGCAACAGAGC-
AGTG-30 for IL-10 promoter; 50-GCGTCTAGAGTGCC-
ATCCAAAGTGTTGTA-30 and 50-GAGGAATTCACAA-
TGTGCTGCACCTCCTCT-30 for IFN-gamma promoter;
50-TATGAATTCCTGTATGCCTCCCTGAGGG-30 and
50-TGTTCTAGACTGCTGTTGCTGGTACTGG-30 for
IL-12 p40 promoter; 50-TGAGGAATGGGTTACAGGA-
30 and 50-CCTCTGCTGTCCTTGCTGA-30 for TNF-alpha
promoter. Ampliﬁcation was performed using Advantage2
PCR kit (Clontech, Palo Alto, CA) in 25 cycles (95 for
30s, 588 for 90s). PCR products were digested with XbaI
and EcoRI restriction enzymes and cloned into pGEM-7
(for IL-12 p40 and IFN-gamma promoter sequences) or
directly cloned into pGEM-T vector (both Promega) and
sequenced using SP6 and T7 primers. Sequences were
analyzed using DNASTAR analysis package and putative
transcription factor (TF) binding sites were located using
TFSEARCH software (Y. Akiyama, RWCP, Japan) and
TRANSFAC database (Heinemeyer et al., 1998).
Sequences from samples from two donors of each species
were analyzed independently and consensus sequence was
generated. Nucleotide sequence data reported are
available in the GenBank database under the accession
numbers: AY486428-AY486436.
IL-4 and IFN-gamma Bioassay
PBMC were cultured in RPMI 1640 (Life Sciences,
Gaithesburg, MD) media supplemented with 10% fetal
calf serum (Cellgro), L-glutamine and gentamycin (both
Life Sciences). Cells were stimulated with 10mg/ml of
phytohemagglutinin (PHA-P, DIFCO, Detroit, MI) for
48h and supernatants analyzed for the cytokines as
previously described (Villinger et al., 1993).
RESULTS AND DISCUSSION
T Helper Proﬁle in Nonhuman Primates
Results of previous studies have suggested that the
spectrum of T helper cell response based on the synthesis
of cytokines plays an important role in the outcome of
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prototype Th2 cytokines—such as IL-10 and IL-4—and
decrease in the prototype Th1 cytokines—such as IFN-
gamma and IL12—was shown to be associated with
infection and/or with rapid disease progression in HIV
infected humans (Stylianou et al., 1999) and SIV infected
macaques (Benveniste et al., 1996a). Our previous
analysis of random cloned cell lines from rhesus macaques
(RM) and SM showed that, interestingly, the majority of
the T cell clones (including CD4þ, CD8þ and double
positive) from SM exhibit a Th2phenotype (62 of 93 total)
while a majority of similar clones derived from RM
exhibit a Th1/Th0 phenotype (80 of 89 total) regardless of
SIV status (Ansari et al., 1994). Analysis of the IL-4 and
IFN-gamma levels (major Th2 and Th1 cytokines,
respectively) produced by in vitro PHA stimulated
PBMC cultures from RM and SM show (Fig. 1) that,
indeed, the SM cells produce signiﬁcantly higher level of
IL-4 (Th2) while the RM cells (similar to human cells)
produce signiﬁcantly higher levels of IFN-gamma.
The ﬁnding that RM which are SIV induced disease
susceptible synthesize quantitatively higher levels of IFN-
gamma, a prototype Th1 cytokine, and SM who are SIV
infection disease resistant synthesize relatively higher
levels of IL-4, a prototype Th2 cytokine, presents a
paradox. It is reasonable to assume that in either case the
unique spectrum of cytokines synthesized by PBMC’s
from each of the two species must be—at least in part—
regulated at the transcriptional level by TF and therefore
inﬂuenced by potential polymorphisms within the
promoter regions of the cytokines that may be unique
for the two species. The promoter regions for the
cytokines were therefore ampliﬁed, sequenced and a
comparative analysis performed.
IL-12 p40 Promoter
IL-12 is a major cytokine driving the differentiation of
naı ¨ve T cells into the Th1 phenotype (Manetti et al., 1993;
Mingari et al., 1996). It is a heterodimer consisting of two
subunits—p40 and p35 (Gubler et al., 1991). A signiﬁcant
decrease in the production of IL-12 was observed in
PBMC samples from HIV-1 infected patients that was not
due to negative regulation by IL10 (Chehimi et al., 1994).
The potential effects of HIV infection on the regulation of
IL-12 production are complex and include regulation by
IL-10, TGF-beta, IFN-gamma and other cytokines
(reviewed by Ma and Montaner, 2000).
Analysis of IL-12p40 promoter sequences from RM
and SM showed relatively high degree of variation
among the cytokine promoters analyzed in this report
(Table I). Thus the RM and SM derived promoter
sequences exhibited 95.7% similarity to the human
sequence. While the polymorphic sites were present
throughout the sequence, the promoter region immedi-
ately upstream of the transcriptional start site (up to
position 2130) showed a relatively small degree of
variability with only three identical single base sub-
stituions present in both NHP species (Fig. 2). On the
contrary, the second region—spanning nt 21 3 0u pt o
position 2510—showed multiple variations with several
multinucleotide deletions being the most prominent.
Thus there are two identical deleted regions at positions
2136 and 2168 (2 nt and 9 nt deletions, respectively)
present in both NHP species. While neither of them
targets a known TF binding site the latter one targets a
region previously shown to be protected in DNAse
footprinting assays suggesting the presence of yet an
unknown TF (Becker et al., 2001). There was also an A-
T substitution in both NHP species at position 2230
targeting an AP-1binding site. The promoter region
further upstream, besides showing multiple single
nucleotide substitutions present in both NHP species,
also shows several sequence variation between the two
NHP species. Notably, there is a single C-T substitutions
at position 2345 within the SM derived sequence that
targets a binding site for the transcriptional factor Sp1.
The third and the most distal promoter region analyzed
(2510 to 2730) shows several single bp substitutions
and a deletions, where the C-G substitution at position
2714 and a single nucleotide deletion at position 2514
ﬂanking the NFIL6 binding site are present only in the
SM sequence. An additional single nucleotide variation
that is present at position 2642 is discordant between
the two NHP species—e.g. the substitution is G-C in RM
and G-T in SM. Taken together, the IL-12 p40 promoter
sequence exhibited substantial variability between the
species overall and particularly the two variations
observed in the SM sequence that target binding sites
FIGURE 1 Expression of Th1/Th2 cytokines by PBMC from
nonhuman primates and humans. PBMC from human ðn ¼ 6Þ; RM ðn ¼
10Þ and SM ðn ¼ 10Þ were stimulated with PHA-P and supernatant ﬂuids
assayed for the levels of IL-4 and IFN-gamma by bioassay as previously
described (Villinger et al., 1993).
TABLE I Cytokine promoter sequence pair distances
Length
(bp)*
RM vs. HU
†
(%)
SM vs. HU
(%)
RM vs. SM
(%)
IFN-gamma 750 97.3 97.2 99.6
IL-12 p40 731 95.7 95.7 99.0
IL-10 1171 96.8 96.5 99.1
IL-4 996 96.4 96.9 99.0
TNF-alpha 999 94.4 93.9 98.8
*Length of analyzed sequence.
†Percent similarity between sequences from rhesus macaque (RM), human (HU)
and sooty mangabey (SM).
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in the transcriptional regulation of IL-12 and sub-
sequently in the differences in the Th phenotype
observed between the two NHP species.
IFN-gamma Promoter
IFN-gamma production constitutes an essential part
of Th1 mediated immune response in viral diseases.
In lentivirus induced disease it was shown that
IFN-gamma can restore cell mediated immunity in
cells from HIV infected patients in vitro (De Francesco
et al., 1996). Interestingly however, Nicastri et al.
documented not only a low Th1 cytokine production
(including IFN-gamma) and increased IL-4 in HIV
seropositive subjects but also low IFN-gamma and IL-2
in their HIV exposed seronegative partners suggesting
that perhaps lower levels of these cytokines are
associated with lower levels of cell activation and
may confer a protective effect against infection
(Nicastri et al., 1999). Similarly in SIV model of
AIDS in nonhuman primates, analysis of unstimulated
expression of cytokines showed increase in IL-2 and
IFN-gamma in RM but a similar increase of only IL-10
in SM after experimental infection with SIVmac239 in
both species (Kaur et al., 1998), providing evidence for
an association between increased IFN-gamma levels
with pathogenic SIV infection in RM. Yet another study
by Orandle et al. showed a positive correlation between
IFN-gamma levels and SIV infection with concurrent
neuropathology (Orandle et al., 2001).
Analysis of IFN-gamma regulatory sequences in a
cohort of Caucasian HIV patients showed very little
polymorphism, in fact the sequences upstream of TATA
box (up to position 2777) were invariant in both HIV
positive subjects and controls (Bream et al., 2000).
Interestingly, a recent study in an African–American
cohort showed a positive association of 2179 G-T
IFN-gamma promoter polymorphism with accelerated
progression of HIV disease (An et al., 2003).
FIGURE 2 Sequence analysis of IL-12 p40 promoter. IL-12 p40 promoter sequences from SM and RM were aligned to the corresponding human
sequence (HU). The numbering reﬂects positions in the human sequence. Highly variable region (2130 to 2729) is shown; sequence deletions are
marked by “x” and binding sites of selected TFs are underlined. “*” Marks a region protected in DNAse footprinting assays suggesting the presence of
yet an unknown TF (Becker et al., 2001).
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sequences (up to 2750) showed .97% similarity
between each of the NHP species and humans which
represented the lowest degree of variation of all the
promoter regions studied (Table I). The whole region
contained only 11 identical single bp substitutions and two
identical single bp insertions that were present in the
two NHP species when compared to human sequence.
The sequences from both NHP species also exhibited the
highest degree of homology when compared to each other
(99.6%) with each sequence containing only one single nt
variation. Neither of the NHP sequences contained the
2179 G-T polymorphism.
The low degree of variability between the IFN-gamma
promoter sequences from the two species suggests it is
unlikely that the observed differences in Th phenotype in
these species are secondary to the sequence variations
within the proximal promoter sequences.
TNF-alpha Promoter
TNF-alphaisanimportantcytokineinvolvedinHIVinduced
apoptosis of CD4þ Tc e l l s( K l e i net al., 1996) and was
shown to play an important role in HIV gp120 mediated
CD4þ T cell anergy (Kaneko etal., 1997).Increased levels
ofserumTNF-alphawereshowntocorrelatewithadvanced
HIV disease (Havlir et al., 2001) and SIV infection in
macaques (Benveniste et al., 1996a). TNF-alpha was also
showntoactivateHIV-1replicationininfectedcellsinvitro
(Folks et al., 1989) and to function as a mediator of HIV tat
induced activation of monocytes (Lafrenie et al.,1 9 9 7 ) .
Several polymorphisms of the TNF-alpha promoter
sequence (G-A at positions 2376, 2308, 2244 and
2238) have been shown to associate with altered course of
HCV infection (Lio et al., 2003), malaria (May et al.,2 0 0 0 )
and leprosy (Santos et al., 2002).
Potential effect of TNF-alpha promoter polymorphism
in AIDS progression has been also studied and Quasney
et al. showed a link between the presence of the A allele at
position 2308 and AIDS dementia (Quasney et al., 2001).
However, other reports failed to establish a link between
this polymorphism and disease progression (Brinkman
et al., 1997; Knuchel et al., 1998). Since we have
previously showed that SM exhibit ,50% lower levels of
serum TNF-alpha than humans or RM (Villinger et al.,
1993) it was of interest to investigate whether potential
TNF-alpha promoter sequence polymorphisms could be
associated with this phenotype. The analysis showed that
the RM and SM TNF-alpha promoter sequences show the
highest degree of diversity to (94.4% and 93.9% similarity
the published human sequence, respectively) of all the
promoter sequences analyzed. While the detected
diversity of sequences is mostly caused by isolated single
base substitutions or deletions that in most cases are
present in both NHP species there are several regions in
the promoter where the monkey sequences exhibit
substantial degree of diversity between the two NHP
species (Fig. 3).
Interestingly, both species show G-A polymorphisms at
positions 2376 and 2308. While AP-1, AP-2 and Sp1
binding sites immediately upstream of TATA box are not
targeted by any sequence variations, there is a 3 bp
deletion in the region between the closely spaced Sp1 and
AP-2 sites in both monkey species and an additional single
bp substitution in SM sequence only (Fig. 3B). Sequence
between positions 2260 and 2885 represents another
variable region (Fig. 3A). The downstream part of this
region (2467 to 2630) shows ﬁve different insertion
points and several substitutions. There are three 2 bp
insertions at positions 2467, 2504 and 2627 and one
1 bp insertion at position 2538 (targeting the putative Sp1
binding site) that are identical in both monkey species.
However, there is also a discordant 2 bp insertion in RM
sequence vs. 1 bp insertion in SM sequence at position
2591 targeting putative c-Rel TF binding site. Another
region with a high sequence diversity was detected in
upstream promoter sequences (Fig. 3A, region 2660 to
2885). This region exhibited two deletions (positions
2853 and 2868) targeting the myeloid zinc-ﬁnger factor
1 TF (MZF1) binding site and ﬂanking the NF-kappaB TF
binding site that were identical in both monkeys, but SM
sequence exhibited an extra single bp deletion at position
2856. In addition, the SM sequence contained an
additional single bp deletion (position 2811), two 1 bp
insertions (positions 2738 and 2767) and three 1 bp
substitutions (2661, 2704 and 2741). Taken together,
the sequences exhibit the lowest relative degree of
homology overall and there are several regions exhibiting
diverse sequence variations speciﬁc for SM that could be
one of the mechanisms involved in the observed
phenotype represented by the lower levels of TNF-alpha
detected in the serum of this species.
IL-10 Promoter
IL-10 is a potent cytokine involved in the regulation of Th
type immune responses and increased IL-10 levels have
been associated with rapid disease progression in HIV
infected humans (Stylianou et al., 1999) and with SIV
infection in macaques (Benveniste et al., 1996a).
The increased levels of IL-10 were shown to negatively
affect responses to recall antigens in HIV infected humans
(Daftarian et al., 1995), but on the other hand. IL-10 was
also shown to inhibit HIV replication in human
monocytes/macrophages (Akridge et al., 1994). One of
the mechanisms potential responsible for the differential
IL-10 expression in HIV-1 infected individuals is the
association of select polymorphisms within the IL-10
promoter with faster/delayed disease progression
(Shin et al., 2000). Analysis of IL-10 promoter sequences
from RM revealed several sequence variations in
upstream and downstream promoter sequences (Fig. 4A
and B) identical to those previously described (Kumarvelu
et al., 2001) and that are present, in most cases in SM as
well. Thus we observed a unique and extensive insertion
of 9 nt sequence at position 2715. Computer analysis
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created binding site for N-myc. Interestingly, this
sequence insertion is identical in both SM and RM
monkeys—which may indicate that it probably is not one
of the variations potentially underlying the observed
differences in Th phenotype and/or SIV disease
resistance/susceptibility. Also several point substitutions
and/or insertions previously described were observed in
both monkey species. We detected only one 3 bp deletion
(position 2255), rather than three deletions closely
spaced together (Kumarvelu et al., 2001), which is present
in both NHP species. The Sp1 site (2631 to 2637)
previously described to be crucial for IL-10 induction
following stimulation with LPS (Ma et al., 2001) bears
C-T polymorphism that is, however also present in both
primate species. Neither monkey species exhibited the
2592 polymorphism that was previously described to be
associated with differential rate of AIDS disease
progression in humans (Shin et al., 2000).
Interestingly we detected several polymorphic sites
within the IL-10 promoter that were represented by single
nucleotide substitutions that were present in SM derived
sequences, but not in RM or human derived promoters.
Speciﬁcally there was G-A substitution in SM at position
2864 that targets the center of one of the C/EBP binding
sites previously shown to be important for cAMP
mediated upregulation of IL-10 transcription (Brenner
et al., 2003). More importantly, two observed single base
substitutions (T-C at position 2804 and C-T at position
2562) created two potential binding sites for the
transcriptional factor p300. In addition a G-A substitution
at position 2949 created a putative binding site for Oct1
and A-C substitution at position 2750 created a putative
binding site for MZF1.
FIGURE 3 Sequence analysis of TNF-alpha promoter. TNF-alpha promoter sequences from SM and RM were aligned to the corresponding human
sequence (HU). The numbering reﬂects positions in the human sequence. Highly variable regions upstream (A) and adjacent (B) to the TATA box are
shown. Sequence deletions are marked by “x”, insertions by “ ¼ ” and binding sites of selected TFs are underlined. “*” Marks G-A polymorphisms at
positions 2308 and 2376.
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RM compared with the human derived sequence are also
present in the SM monkeys, there are several discrete
polymorphisms speciﬁc for SM derived sequence that—
although primarily consisting only of single nucleotide
substitutions—create putative binding sites for well
described TFs that may contribute to the differential
regulation of IL-10 expression with the observed skew in
the Th type response.
IL-4 Promoter
IL-4 is one of the major cytokines involved in Th2
polarization (Parronchi et al.,1992) and has been shownto
downregulate IL-12p40 (Th1 cytokine) production at both
the transcriptional and the post-transcriptional levels
(Seegmuller et al., 2003). Several studies have addressed
the potential role of IL-4 promoter polymorphisms and
IL-4 levels in HIV disease. Thus decrease of IL-4
(and IFN-gamma) levels was found to be associated
with neurological complications in AIDS patients
(Wesselingh et al., 1994). While one study found the
2590 C-T polymorphism was associated with HIV
disease (Smolnikova and Konenkov, 2002), the results
from another study suggested that this polymorphism was
associated with a delayed acquisition of CXCR4 tropic
HIV variants, but with no effect on disease progression
(Kwa et al., 2003).
In our analysis of the protype Th1/Th2 cytokines in RM
and SM we found that PHA stimulated PBMC from SM
express signiﬁcantly higher levels of IL-4 when compared
with similar cells from humans or RM (Fig. 1). However,
when we cloned and sequenced the IL-4 promoter from
each of the two nonhuman primate species, we found a
relatively high degree of homology between the sequences
from different species (Table I). Speciﬁcally, very little
sequence variation was observed within the very proximal
promoter sequences—e.g. the sequences were completely
homologous up to position 2200 upstream of the start site
and exhibited ,98.2% homology up to position 2540.
Within this region all the variations found are present in
both RM and SM (compared to humansequence) and none
FIGURE 4 Sequence analysis of IL-10 promoter. IL-10 promoter sequences from SM and RM were aligned to the corresponding human sequence
(HU). The numbering reﬂects positions in the human sequence. Highly variable upstream (A) and downstream (B) promoter regions are shown.
Sequence deletions are marked by “x”, insertions by “ ¼ ” and binding sites of selected TFs are underlined. Underlined bases in SM derived sequence
indicate predicted biding site created by sequence variation. “*” Marks G-A polymorphisms at positions 2308 and 2376.
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(Fig. 5B). On the contrary, sequences between positions
2540 and 2950 exhibit substantial variations (,10%)
between the nonhuman primate and human sequences and
some of this variation is discordant between the SM and
RM (Fig. 5A). Notably there is an insertion at position
2554 in the SM sequence that creates a potential binding
site for C/EBP, a TF previously shown to play an
important role in the regulation of IL-4 transcription
(Berberich-Siebelt et al., 2000). Moreover, there is a
signiﬁcant insertion in both RM and SM (3 and 4 bp,
respectively) within the poly A region at position 2670.
The region further upstream in the NHP sequences
contains numerous single bp substitutions (where two are
discordant between SM vs. RM and/or humans) as well as
four 1 single bp insertion and one 2 bp deletion. The 2590
site does not show any variation in these two NHP species.
Taken together, the fact that the proximal IL4 promoter
from each of the species exhibited a relatively high degree
of homology seems to indicate that the observed species
speciﬁc differences in IL-4 expression are probably
not based on a genetic predisposition leading to
the differential binding of the appropriate TF. However,
it is possible that the creation of the additional C/EBP
binding site can positively affect IL-4 transcription in SM.
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